Short description
Oncodesign develops anticancer therapies for the treatment of patients with cancer.
Description
Pharmacological expertise for anticancer therapies from target to patient : a unique oncology preclinical CRO.
Founded in 1995, Oncodesign is a biopharmaceutical company that fills in the innovation gaps in the healthcare industry, based on its unique precision medicine platform. Technological innovation lies at the heart of Oncodesign’s model—the Etiology, Discovery and Experimentation activities designed and implemented by Oncodesign contribute to a more effective approach to the phenomenon of innate and acquired resistance, more effective treatments and a reduction in therapeutic failures.
Working alongside big pharma, biotech’s, public research institutions and investment groups, Oncodesign orients the research and development of new therapeutic and diagnostic tools. Through its range of services, partnerships and licensing programs, Oncodesign’s offering can meet the full range of innovation needs.
Oncodesign is listed on the Euronext Growth Paris market and possesses a stable ownership structure with a majority owner committed to its development.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Dijon, Bourgogne, France, Europe
Founded on
January 1, 1995
Exited on
April 11, 2014
Went public on
April 11, 2014
Stock symbol
AlONC
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccessforu, Nopepepe, Absolutely Noaccess, Uh Ohhhh, Cannot Access, Nopepepe, Uh Ohhhh
Sign in for full access
Founders
Philippe Genne